The aim: Is to evaluate copetin’s, MRproADM’s and troponin’s I dynamic in patients with acute myocardial infarction depending on the degree of concomitant obesity. Material and methods: The study included 105 patients with AMI. There were formed 2 groups: 1st group of patients with AMI and concomitant obesity (n=75), 2nd group – patients with AMI without obesity (n=30). 37 patients had obesity of the I degree, 38 patients - II degree. The groups were comparable in age and gender. Copeptin, MRproADM, troponin I were determined by enzyme immunoassay method. Data are presented as mean values and the error of the mean (M±m). Differences were considered statistically significant at p<0,05. Results: It was found an increased copeptin’s level by 73,8 % (p<0,001) in obesity I degree and by 205,9 % in obesity II degree compared with group with isolated AMI, MRproADM - by 30,68 % (p<0,001) and 54,5 % (p<0,001) respectively. Concentration of copeptin was higher by 76 % (p<0,001) in patients with AMI and II degree obesity comparing to patients with obesity of I degree, and MRproADM - by 18,3% (p<0,001) respectively. Troponin I value fully corresponded the comparison group both in obesity of I degree and II degree (p>0,05). Conclusions: The present study provides evidence that a high activity of copeptin and MRproADM in patients with AMI and obesity of I degree with an excessive activity of a marker of vasoconstriction copeptin in conditions of moderate inadequate to the needs MRproADM functioning in patients with obesity of II degree.
The review is about study of the interlinks of obesity and cardiovascular disease occurrence. It is shown the effect of adipose tissue on the prognosis of cardiovascular diseases, both acute and chronic forms of chronic heart disease, chronic heart failure. Problem of «paradox of obesity» is still an actual and debatable problem of modern medicine of internal diseases. Further researches are needed to study the relationship between adipose tissue and the cardiovascular system abnormalities.
The aim of the study-to evaluate the condition of the coronary arteries according to quartile of galectin-3 serum level in patients with acute myocardial infarction and obesity.
Object and methods. The study involved 87 patients with AMI. The first group consisted of 48 patients withconcomitant obesity, the second group — of 39 patients with normal body weight. The assessment of the qualityof life was performed using the nonspecific questionnaire «SF-36 Health Status Survey», troponin I, total cholesterol, cholesterol of high-density lipoproteins, cholesterol of low-density lipoproteins levels.The presence of obesity is associated with a significant decrease of the quality of life in patients with acutemyocardial infarction in comparison to patients who have normal body weight through physical and psychoemotional components of health. The leading lines concerning poor quality of life are the scales of role functioning, due to physical condition and vitality, that indicate the patients’ fatigue on the background of obesity, feeling exhausted and display the cognitive dissonance that may affect the patient complience. The comorbidity ofAMI and obesity is associated with the atherogenic changes of lipid profile and more severe hypertroponinemia.
The aim: To study the nesfatin-1 activity in the blood serum of patients with chronic heart failure (CHF) of ischemic origin against the background of such metabolic disorders as type 2 diabetes mellitus (T2DM) and obesity. Materials and methods: 154 patients with CHF were examined, and divided into 4 groups, according to the presence of metabolic disorders. Group 1 included patients with CHF on the background of coronary heart disease (CHD) and T2DM and obesity (n=42). The second group consisted of patients with heart failure on the background of CHD with concomitant T2DM (n=46), the third group - with concomitant obesity (n=36), the fourth group was formed from patients with signs of heart failure of ischemic origin without metabolic disorders (n=30). The control group (CG) included 30 practically healthy persons of comparable age. Results: The mean level of serum nesfatin-1 was 1.64±0.27 ng/mL in the СHF group, 0.342±0.19 ng/mL in the CHF + T2DM + obesity group, 1.06±0.36 ng/ mL in the obese + CHF group, 0.96±0.27 ng/mL in the CHF + T2DM group and 2.98±0.38 ng/mL in the CG. Significant correlation was found between the serum nesfatin-1 level and BMI (r=–0.34, p<0.05), HOMA (r=–0.54, p<0.05), insulin (r=–0.41, p<0.05). No significant correlation was found between the serum nesfatin-1 level and blood glucose level (r=0.13, p=0.65). Conclusions: Thus, nesfatin-1 may play a significant role in the pathogenesis of both weight-related abnormalities and type 2 diabetes mellitus in patients with chronic heart failure of ischemic origin.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.